New Publication in Vaccine Highlights Preclinical Results of Vaxart’s Mucosal Chikungunya Vaccine
May 29 2019 - 8:00AM
Business Wire
Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology
company developing oral recombinant vaccines that are administered
by tablet rather than by injection, today announced the publication
of the comprehensive results from a preclinical trial of its
chikungunya vaccine in the peer reviewed journal, Vaccine.
The article, titled “An adjuvanted adenovirus 5-based vaccine
elicits neutralizing antibodies and protects mice against
chikungunya virus-induced footpad swelling,” details the results
from a study using Vaxart’s chikungunya vaccine candidate in a
preclinical efficacy model.
“These preclinical results demonstrate that our vaccine
candidate induced significant neutralizing antibodies against
chikungunya virus as well as protective efficacy against
virus-induced pathologic changes,” said Sean Tucker, Ph.D., founder
and chief scientific officer of Vaxart. “Importantly, we saw
reduced footpad swelling, a model for arthritis induction in humans
caused by chikungunya infection. There are no approved vaccines or
treatments for the estimated one million patients each year
infected with chikungunya virus.”
Vaxart develops oral vaccines for a broad range of infections
that have a major impact on public health, including vaccines for
norovirus and influenza.
About Chikungunya
Chikungunya is an illness caused by a virus that spreads through
mosquito bites. The most common symptoms of chikungunya are fever
and joint pain. Other symptoms may include headache, muscle pain,
joint swelling, or rash. The mosquito that carries chikungunya
virus bites primarily during the daytime, both indoors and
outdoors, and often lives around buildings in urban areas. Patients
symptoms usually begin 3—7 days after being bitten by an infected
mosquito. Most patients will feel better within a week. In some
people, the joint pain may persist for months. Death is rare.
People at risk for more severe disease include newborns infected
around the time of birth, older adults (≥65 years), and people with
medical conditions such as high blood pressure, diabetes, or heart
disease. Travelers who go to Africa, Asia, parts of Central and
South America, and islands in the Indian Ocean, Western and South
Pacific, and Caribbean are at risk.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on
developing oral recombinant protein vaccines based on its
proprietary oral vaccine platform. Vaxart’s vaccines are designed
to generate broad and durable immune responses that protect against
a wide range of infectious diseases and may also be useful for the
treatment of chronic viral infections and cancer. Vaxart’s vaccines
are administered using a convenient room temperature-stable tablet,
rather than by injection. Vaxart believes that tablet vaccines are
easier to distribute and administer than injectable vaccines and
have the potential to significantly increase vaccination rates.
Vaxart’s development programs include oral tablet vaccines that are
designed to protect against norovirus, seasonal influenza and
respiratory syncytial virus (RSV), as well as a therapeutic vaccine
for human papillomavirus (HPV).
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding our strategy, prospects, plans and objectives, results
from preclinical and clinical trials, commercialization agreements
and licenses, beliefs and expectations of management are
forward-looking statements. These forward-looking statements may be
accompanied by such words as “believe,” “could,” “potential,”
“will” and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements
relating to the Vaxart’s ability to develop and commercialize its
product candidates and clinical results and trial data; the
expected timing of the initiation of the Phase 1 bivalent study and
Phase 2 monovalent challenge study; and Vaxart’s expectations with
respect to the important advantages it believes its oral vaccine
platform can offer over injectable alternatives, particularly for
mucosal pathogens such as norovirus, flu and RSV. Vaxart may not
actually achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in our forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that Vaxart makes, that
Vaxart’s product candidates may not be approved by the FDA or
non-U.S. regulatory authorities; that, even if approved by the FDA
or non-U.S. regulatory authorities, Vaxart’s product candidates may
not achieve broad market acceptance; that Vaxart may experience
manufacturing issues and delays; and other risks described in the
“Risk Factors” sections of Vaxart’s Quarterly and Annual Reports
filed with the SEC. Vaxart does not assume any obligation to update
any forward-looking statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190529005267/en/
Daniella FunaroStern Investor
Relations212-362-1200vaxart@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Sep 2023 to Sep 2024